Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape
Oct 10, 06:07 PM
Share
Subscribe
In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and market implications of the Most Favored Nation drug pricing proposal, and the FDA’s approval of Libtayo as an adjuvant therapy for cutaneous squamous cell carcinoma.